Pneumocystis jirovecii pneumonia

Background

  • Pneumocystis (carinii) jiroveci
  • Most common opportunistic infection in AIDS pts
  • Most common identifiable cause of death
  • Risk factors:
    • CD4 < 200
    • Immunosuppressive medications
    • Cancer
    • Primary immunodeficiencies
    • Severe malnutrition

Clinical Features

  • Fever (62%)
  • Dry cough
  • Shortness of breath (progressive from exertion only to at rest)

Diagnosis

  • Imaging
    • CXR
      • Normal in 25% of cases
      • Diffuse, interstitial infiltrates
    • CT Chest
      • Sn 100%, Sp 89%
      • May see ground glass infiltrative pattern
  • Labs
    • LDH
      • Low Sn, Sp
    • ABG
      • Hypoxemia, increased A-a gradient

Work-Up

  • CBC
  • Chemistry
  • LDH
  • ABG
  • CD4 count
  • CXR - bat wing appearance (bilat interstitial infiltrates)
  • A-a gradient
    • P(A-a)O2 = 145 – PaCO2 – PaO2 (normal is <10 in young, healthy pts)

DDX

Treatment

Antibiotics

Mild Disease

  • TMP/SMX 2 DS tablets PO q8hrs OR
    • High incidence of allergy in HIV
  • Dapsone 100mg PO once daily + TMP 5mg/kg PO q8hrs OR
    • caution: dapsone can cause methemoglobinemia
  • Atavaquone 750mg PO q12hrs OR
  • Primaquine 30mg PO q24hrs + Clindamycin 450mg PO q8hrs

Severe Disease

Prophylaxis

  • TMP/SMX 1 DS tablet daily, but one single strength tablet daily or one double-strength three times weekly is acceptable.[1]

Pediatric Treatment

  • TMP/SMX 5mg/kg (TMP) IV/PO q6-8hrs x 21 days
  • Pentamidine 4mg/kg IV daily x 21 days if TMP/SMX intolerant
  • Dapsone 2mg/kg/day PO (max 100mg) + TMP 15mg/kg/day PO divided TID for mild disease

Pediatric Prophylaxis

  • TMP/SMX 5mg/kg/day (TMP) PO divided BID 3 days/week (first line)
  • Dapsone 2mg/kg/day PO daily (max 100mg) or Atovaquone as alternatives

Disposition

  • Symptoms usually worsen 2-3d after start of treatment
  • Pts w/ disease severe enough to warrant IV therapy or steroids should be admitted

Source

  1. CDC Guidelines for Prophylaxis Against Pneumocystis carinii Pneumonia for Children Infected with Human Immunodeficiency Virus http://www.cdc.gov/mmwr/preview/mmwrhtml/00001957.htm